SCHEMBL771374

SCHEMBL771374

O=C(NCCC(=O)N1CCCC2CCCCC21)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.48
PREP P48147 2/20 0.48
FAP Q12884 2/20 0.48
EPHX1 P07099 1/20 0.44
NAAA Q02083 1/20 0.42
ITGB3 P05106 8/20 0.42
ITGA2B P08514 8/20 0.42
F2R P25116 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
CHRM1 P11229 1/20 0.40
PKM P14618 1/20 0.40
EPHX2 P34913 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772214 0.99 DPP4 (0.47) DPP4PREPFAPEPHX1NAAA
SCHEMBL770588 0.92 NAAA (0.47) DPP4PREPFAPEPHX1NAAA
SCHEMBL770879 0.87 DRD2 (0.39) DPP4PREPFAPITGB3ITGA2B
SCHEMBL769965 0.84 NPC1 (0.50) DPP4SMN1; SMN2NPC1RAB9ADRD2
SCHEMBL771679 0.84 NPC1 (0.47) DPP4SMN1; SMN2NPC1RAB9ADRD2
SCHEMBL770636 0.81 EPHX2 (0.51) EPHX1SMN1; SMN2NPC1RAB9AEPHX2
SCHEMBL771009 0.81 EPHX2 (0.51) EPHX1SMN1; SMN2NPC1RAB9AEPHX2
SCHEMBL771394 0.81 HSD11B1 (0.42) DPP4SMN1; SMN2NPC1RAB9ADRD2
SCHEMBL771098 0.80 ALDH1A1 (0.46) SMN1; SMN2
SCHEMBL771464 0.80 DRD2 (0.51) PREPFAPSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DPP4 1092/4885PREP 900/4885FAP 2352/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 DPP4 1125/4885PREP 907/4885FAP 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.